ranolazine has been researched along with propafenone in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Antzelevitch, C; Belardinelli, L; Burashnikov, A; Di Diego, JM; Zygmunt, AC | 1 |
| Antzelevitch, C; Belardinelli, L; Burashnikov, A | 1 |
1 review(s) available for ranolazine and propafenone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for ranolazine and propafenone
| Article | Year |
|---|---|
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Electrophysiology; Heart Atria; Humans; Lidocaine; Piperazines; Propafenone; Ranolazine; Sodium Channel Blockers; Ventricular Function | 2008 |
Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Diastole; Dogs; Electrophysiological Phenomena; Heart Atria; Heart Conduction System; Heart Ventricles; Kinetics; Piperazines; Propafenone; Ranolazine; Refractory Period, Electrophysiological; Sodium Channel Blockers | 2012 |